AnaptysBio (NASDAQ:ANAB) Issues Quarterly Earnings Results

AnaptysBio (NASDAQ:ANAB) issued its earnings results on Monday. The biotechnology company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82), Yahoo Finance reports. AnaptysBio had a negative return on equity of 161.40% and a negative net margin of 711.17%. The company had revenue of $10.97 million during the quarter, compared to the consensus estimate of $25.85 million.

AnaptysBio Trading Down 1.7 %

Shares of ANAB stock traded down $0.54 during trading hours on Wednesday, reaching $31.54. 230,569 shares of the company’s stock were exchanged, compared to its average volume of 328,963. The stock has a market cap of $861.64 million, a PE ratio of -5.16 and a beta of -0.25. The stock’s fifty day moving average price is $28.03 and its two-hundred day moving average price is $25.11. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $38.85.

Insider Buying and Selling

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. Following the transaction, the insider now owns 11,618 shares in the company, valued at approximately $406,630. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other AnaptysBio news, Director Hollings Renton sold 10,000 shares of AnaptysBio stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $30.64, for a total transaction of $306,400.00. Following the completion of the sale, the director now directly owns 1,950 shares in the company, valued at approximately $59,748. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. Following the completion of the sale, the insider now directly owns 11,618 shares in the company, valued at $406,630. The disclosure for this sale can be found here. Insiders sold 16,900 shares of company stock worth $484,824 in the last three months. Corporate insiders own 33.70% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Leerink Partnrs reissued an “outperform” rating on shares of AnaptysBio in a research note on Tuesday, April 16th. SVB Leerink started coverage on AnaptysBio in a research note on Tuesday, April 16th. They set an “outperform” rating and a $47.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of AnaptysBio in a research note on Tuesday. Wedbush reissued an “outperform” rating and set a $34.00 target price on shares of AnaptysBio in a research report on Friday, May 10th. Finally, JPMorgan Chase & Co. increased their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average price target of $52.56.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.